GLP-1 Coverage Is COLLAPSING in 2027
Summary
Host Dave Knapp discusses the shrinking access to GLP-1 medications as employers and states pull back coverage due to costs. He contrasts this with patient-led strategies like intermittent dosing, highlighted by Emily Simpson, to manage weight maintenance. The episode explores the tension between immediate healthcare expenses and long-term metabolic health benefits, questioning if lower-dose therapies could become standard for disease prevention.
Topics discussed
Intro: GLP-1 access crisis and maintenance strategies
Host intro and VoaFit sponsorship
States opting out of Medicaid GLP-1 coverage model
Why states fear the cost of expanded obesity treatment
Patient perspective: Access barriers and compounded options
Employers dropping GLP-1 coverage and future drug pipeline
The economic disconnect: Who pays vs who saves?
Emily Simpson's intermittent dosing strategy
Microdosing science, diet culture, and normal eating
Connecting access costs to patient maintenance choices
Listen ad-free on Castria